Several regulatory decisions are scheduled in the United States in November 2026. Among them is asundexian, an oral factor XIa inhibitor under priority review for secondary stroke prevention.
Decisions are also expected on treatments for myasthenia gravis, primary biliary cholangitis, breast cancer, and on bezuclastinib combined with sunitinib for gastrointestinal stromal tumours (GIST) after imatinib.
Source: Endocrinology Advisor















